MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592285 | Name: Mitolactol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mitolactol is an alkylating antineoplastic toxic to bone marrow; used in breast cancer, also in combination with other drugs. Mitolactol is able to cross bloodbrain barrier, consequently could control certain brain tumors.

Chemical Structure

Mitolactol
Mitolactol
CAS#10318-26-0

Theoretical Analysis

MedKoo Cat#: 592285

Name: Mitolactol

CAS#: 10318-26-0

Chemical Formula: C6H12Br2O4

Exact Mass: 205.9102

Molecular Weight: 305.97

Elemental Analysis: C, 23.40; H, 3.93; Br, 51.89; O, 20.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mitolactol; NSC 104800; NSC-104800; NSC104800
IUPAC/Chemical Name
1,6-Dibromo-1,6-dideoxy-D-galactitol
InChi Key
VFKZTMPDYBFSTM-GUCUJZIJSA-N
InChi Code
InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4+,5+,6-
SMILES Code
O[C@H]([C@H]([C@H]([C@@H](CBr)O)O)O)CBr
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 305.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Jeney A, Kralovánszky J, Lapis K. [Anticancer drug research in Hungary, 1950-2000]. Magy Onkol. 2017 Dec 18;61(4):375-382. Epub 2017 Nov 30. Hungarian. PubMed PMID: 29257158. 2: Qi L, Ding L, Wang S, Zhong Y, Zhao D, Gao L, Wang W, Lv P, Xu Y, Wang S. A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). Oncotarget. 2016 Oct 18;7(42):69002-69013. doi: 10.18632/oncotarget.10763. PubMed PMID: 27458167; PubMed Central PMCID: PMC5356607. 3: Ishiyama T, Jinguu A, Matsumoto H, Kikuchi J, Suzuki T, Yamakawa M. [A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen]. Gan To Kagaku Ryoho. 2012 Aug;39(8):1287-9. Japanese. PubMed PMID: 22902461. 4: Olasz L, Orsi E, Markó T, Szalma J. Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC). Cancer Metastasis Rev. 2010 Dec;29(4):607-11. doi: 10.1007/s10555-010-9259-7. Review. PubMed PMID: 20842409. 5: Mishra KK, Squire S, Lamborn K, Banerjee A, Gupta N, Wara WM, Prados MD, Berger MS, Haas-Kogan DA. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol. 2010 Oct;100(1):121-7. doi: 10.1007/s11060-010-0151-7. Epub 2010 Mar 11. PubMed PMID: 20221671; PubMed Central PMCID: PMC2951507. 6: Song X, Wang JB, Yin DL, Yang HY, Liu LX, Jiang HC. Down-regulation of lung resistance related protein by RNA interference targeting survivin induces the reversal of chemoresistances in hepatocellular carcinoma. Chin Med J (Engl). 2009 Nov 5;122(21):2636-42. PubMed PMID: 19951584. 7: Olasz L, Szalma J, Orsi E, Tornóczky T, Markó T, Nyárády Z. Neoadjuvant chemotherapy: does it have benefits for the surgeon in the treatment of advanced squamous cell cancer of the oral cavity? Pathol Oncol Res. 2010 Jun;16(2):207-12. doi: 10.1007/s12253-009-9208-3. Epub 2009 Sep 12. PubMed PMID: 19757193. 8: Tsai HC, Yeh TL, Hsieh MH, Lee IH, Chen KC, Chen PS, Yang YK, Yao WJ. Association between serotonin transporter availability and overall rating scores of quality of life in healthy volunteers. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):711-4. doi: 10.1016/j.pnpbp.2009.03.018. Epub 2009 Mar 28. PubMed PMID: 19332100. 9: Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ; EORTC Brain Tumour Group investigators. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008 Jun;44(9):1210-6. doi: 10.1016/j.ejca.2007.12.005. Epub 2008 Jan 14. PubMed PMID: 18248979. 10: Wei L, Song XR, Wang XW, Li M, Z uo WS. [Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance]. Zhonghua Zhong Liu Za Zhi. 2006 Jun;28(6):445-8. Chinese. PubMed PMID: 17152492. 11: Burzynski SR. Treatments for astrocytic tumors in children: current and emerging strategies. Paediatr Drugs. 2006;8(3):167-78. Review. PubMed PMID: 16774296. 12: Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC, Head DR, Stine KC, Lacayo NJ, Sikic BI, Arceci RJ, Weinstein H; Pediatric Oncology Group. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood. 2006 Feb 15;107(4):1315-24. Epub 2005 Oct 27. PubMed PMID: 16254147; PubMed Central PMCID: PMC1895393. 13: Olasz L, Nyárády Z, Németh A, Királyfalvi L, Ember I. Failure of alkylating agents to improve induction chemotherapy of oropharyngeal squamous cell cancer. Anticancer Res. 2004 Jul-Aug;24(4):2557-61. PubMed PMID: 15330214. 14: Nakamura T, Kato Y, Fuji H, Horiuchi T, Chiba Y, Tanaka K. E-cadherin-dependent intercellular adhesion enhances chemoresistance. Int J Mol Med. 2003 Nov;12(5):693-700. PubMed PMID: 14532995. 15: Vitanovics D, Sipos L, Afra D. BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas. Neoplasma. 2002;49(5):342-5. PubMed PMID: 12458335. 16: Afra D, Sipos L, Vitanovics D. [Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)]. Ideggyogy Sz. 2002 Jan 20;55(1-2):38-44. Hungarian. PubMed PMID: 12122942. 17: Bai P, Zhang W, Sun J. [Combination chemotherapy of uterine sarcomas]. Zhonghua Zhong Liu Za Zhi. 2000 Jan;22(1):80-2. Chinese. PubMed PMID: 11776610. 18: Kurosawa K, Takahashi K, Tsuda E, Tomida A, Tsuruo T. Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D. Jpn J Cancer Res. 2001 Nov;92(11):1235-41. PubMed PMID: 11714449; PubMed Central PMCID: PMC5926656. 19: Kraxner H, Tamás L, Sáfrány G, Ribári O, Oláh I, Hidvégi E, Répássy G, Szende B. Apoptotic and mitotic activity in squamous cell carcinoma cells after combined modality treatment with gamma-irradiation and dibromodulcitol. Cell Biol Int. 2001;25(7):599-606. PubMed PMID: 11448098. 20: Levin VA, Lamborn K, Wara W, Davis R, Edwards M, Rabbitt J, Malec M, Prados MD. Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children. Neuro Oncol. 2000 Jan;2(1):22-8. doi: 10.1093/neuonc/2.1.22. PubMed PMID: 11302250; PubMed Central PMCID: PMC1920700.

View History

Mito-HE

Mito-HE